Biologically targeted cancer therapy and marginal benefits: Are we making too much of too little or are we achieving too little by giving too much?

Clinical Cancer Research

Volumn 16, Issue 24, 2010, Pages 5972-5980

  Fojo, Antonio Tito ^a   Parkinson, David R ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Nodality Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; RAS PROTEIN; TAXANE DERIVATIVE; VASCULOTROPIN RECEPTOR;

BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; KRAS GENE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MUTATOR GENE; PANCREAS CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; STOMATITIS;

ACHIEVEMENT; DRUG TOXICITY; DRUGS, INVESTIGATIONAL; EFFICIENCY; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; QUALITY OF LIFE; RESEARCH DESIGN; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 78650382003     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1277     Document Type: Review

References (56)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
2. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-29.
3. Apperley JF. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1116-28.
4. Sjöblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74.
5. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13.
6. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
7. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
8. Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in nonsmall-cell lung cancer management. Clin Lung Cancer 2009;10:28-35.
9. Moore MJ, Goldstein D, Hamm J, et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
10. Edgerly M, Fojo T. Is there room for improvement in adverse event reporting in the era of targeted therapies? J Natl Cancer Inst 2008;100:240-2.
11. Pirker R, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26:abstract3.
12. Pirker R, Pereira JR, Szczesna A, et al; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31.
13. American Society of Clinical Oncology (ASCO) Press Briefing. Alexandria (VA): ASCO. Available from:http://www.asco.org/ASCO/News/Press+Center/ Annual+Meeting/News+Releases/Advances+in+Lung%2C+Testicular+Cancer
14. Azzoli CG, Baker S Jr, Temin S, et al; American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66.
15. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
16. U.S. Food and Drug Administration. Silver Spring (MD): U.S. Food and Drug Administration. FDA News Release . February 12, 2004: FDA approves erbitux for colorectal cancer. Available from: http://www.medpagetoday.com/MeetingCoverage/ ASCO/9662.
17. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
18. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71.
19. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III Trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME Study. J Clin Oncol 2010;28:4697-705.
20. National Cancer Institute. Bethesda (MD): National Cancer Institute. Erlotinib (tarceva) plus gemcitabine. (Gemzar) for first-line treatment of pancreatic cancer. Available from: http://www.cancer.gov/cancertopics/druginfo/ fda-erlotinib-hydrochloride
21. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72.
22. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-80.
23. U.S. Food and Drug Administration. Silver Spring (MD): U.S. Food and Drug Administration. FDA conditional approval: Bevacizumab in breast cancer. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab
24. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
25. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47.
26. Robert N, Dieras V, Glaspy J, et al. Clinical benefit rate and time to response in RIBBON-1, a randomized, double-blind, phase III trial of chemotherapy with or without bevacizumab (B) for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). Proceedings of the 2009 San Antonio Breast Cancer Symposium ; 2009Dec 9-13; San Antonio (TX). Abstract 6084.
27. Chan A, Miles DW, Pivot X. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Ann Oncol 2010. Epub 2010 Mar 24.
28. O'Shaughnessy J, Dieras V, Glaspy J, et al. Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC). Proceedings of the 2009 San Antonio Breast Cancer Symposium; 2009 Dec 9-13; San Antonio (TX). Abstract 207.
29. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol 2005;23:4.
30. U.S. Food and Drug Administration. Silver Spring (MD): U.S. Food and Drug Administration. FDA approves new combination therapy for lung. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108766.html
31. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12:713-8.
32. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
33. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227- 34[Erratum in: J Clin Oncol 2009;27;2415].
34. Lebwohl D, Kay A, Berg W, Baladi JF, Zheng J. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J 2009;15:386-94.
35. Zhuang SH, Xiu L, Elsayed YA. Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy. Cancer J 2009; 15:395-400.
36. Bach PB. Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs. N Engl J Med 2009;360:626-33.
37. U.S. Food and Drug Administration. Silver Spring (MD): U.S. Food and Drug Administration. About the accelerated approval regulations. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ucm121606.htm
38. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
39. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for kras gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6.
40. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.
41. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS ONE 2009;4:e7287.
42. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009;361:98-9.
43. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
44. Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009;27:5068-74.
45. Balko JM, Black EP. A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer 2009;9:145.
46. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.
47. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
48. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11.
49. Michaud GY. The role of standards in the development and implementation of clinical laboratory tests: a domestic and global perspective. Cancer Biomark 2005;1:209-16.
50. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911-7.
51. Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-smallcell lung cancer. J Clin Oncol 2010;28:918-27.
52. Tsuchihashi Z, Khambata-Ford S, Hanna N, Jänne PA. Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 2005;353:208-9.
53. Booth CM. Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past. Clin Cancer Res 2010;16:5963-71.
54. Smith TJ, Hillner BE. Explaining marginal benefits to patients, when "marginal" means additional but not necessarily small. Clin Cancer Res 2010;16:5981-6.
55. FDA/CDRH public meeting: oversight of laboratory developed tests (LDTs). July 19-20, 2010. Available from: http://www.fda.gov/MedicalDevices/NewsEvents/ WorkshopsConferences/ucm212830.htm
56. U.S. Food and Drug Administration. Silver Spring (MD): U.S. Food and Drug Administration. FDA hoping to regulate laboratory developed tests . Available from: http://www.mpo-mag.com/news/2010/08/03/fda-hoping-to-regulate-laboratory- developed-tests